<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348786</url>
  </required_header>
  <id_info>
    <org_study_id>G1-19</org_study_id>
    <nct_id>NCT04348786</nct_id>
  </id_info>
  <brief_title>Comparing Efficacy of 14-day Therapy Doxycycline With Bismuth Subsalicylate Versus Levofloxacin With Tinadizole on Treatment Helicobacter Pylori</brief_title>
  <official_title>Comparing the Efficacy of 14-day Therapy Doxycycline With Bismuth Subsalicylate Versus Levofloxacin With Tinidazole on Rate of Eradication of Helicobacter Pylori Infected Patients on Syrian Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damascus Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damascus Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison Efficacy of 10-days Therapy with Doxycycline with Bismuth Subsalicylate Versus
      Levofloxacine with Tinadizole on Eradication of Helicobacter Pylori in Syrian population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate of Helicobacter pylori infection</measure>
    <time_frame>8 week from begning of treatment</time_frame>
    <description>Eradication rate of Helicobacter infected patients</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Doxycyclien</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measure eradication rate of Helicobacter pylori infection with Doxycycline and bismuth subsalicylate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Measure eradication rate of Helicobacter pylori infection with Livofloxacine and tinadizole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycylcine 100 mg q.i.d ,esomprazole 20 bid,Bismuth subsalicylate 262 tab.2 tab q.i.d,Tinadizole 500 bid</description>
    <arm_group_label>Doxycyclien</arm_group_label>
    <other_name>Tinadizole</other_name>
    <other_name>Esomeprazole</other_name>
    <other_name>Bismuth subsalicylate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 500mg</intervention_name>
    <description>Levofloxacin 500 mg bid, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid</description>
    <arm_group_label>Levofloxacine</arm_group_label>
    <other_name>Amoxicilline</other_name>
    <other_name>Esomeprazol</other_name>
    <other_name>Tinadiole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients are aged greater than 18 years old who have H. pylori infection diagnosed by
             any of following three methods:

          -  Positive rapid urease test (CLOtest).

          -  Histologic evidence of H. pylori by modified Giemsa staining.

          -  Positive 13C-urea breath test. without prior eradication therapy and are willing to
             receive therapy.

        Exclusion Criteria:

          -  Children and teenagers aged less than 18 years.

          -  Previous eradication treatment for H. pylori.

          -  Patients who took any drug, which could influence the study results such as proton
             pump inhibitor, H2 blocker, mucosal protective agent and antibiotics.

          -  History of gastrectomy.

          -  Gastric malignancy, including adenocarcinoma and lymphoma,

          -  Previous allergic reaction to antibiotics (Amoxicillin, Tinadizole,

          -  Doxycycline,Bismuth subsalicylate,) and prompt pump inhibitors (Es- omeprazole).

          -  Contraindication to treatment drugs.

          -  Pregnant or lactating women.

          -  Severe concurrent disease.

          -  Liver cirrhosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marouf M Alhalabi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>general assambly of damascus hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marouf MH Alhalabi, MD</last_name>
    <phone>+963952781278</phone>
    <email>e.marouf@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Assembly of Damascus Hospital</name>
      <address>
        <city>Damascus</city>
        <country>Syrian Arab Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marouf MI Alhalabi, MD</last_name>
      <phone>+963952781278</phone>
      <email>e.marouf@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Syrian Arab Republic</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Damascus Hospital</investigator_affiliation>
    <investigator_full_name>Marouf Alhalabi</investigator_full_name>
    <investigator_title>head of digestive diseases department</investigator_title>
  </responsible_party>
  <keyword>Doxycyclien</keyword>
  <keyword>Bismuth Subsalicylate</keyword>
  <keyword>Helicobacter Pylori</keyword>
  <keyword>levofloxacine</keyword>
  <keyword>tinadizole</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Bismuth subsalicylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Within 5 year of study completion</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

